PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors
Mónica Tang(Tsan Yuk Hospital), Michael Friedländer(Prince of Wales Hospital), Anna DeFazio(The University of Sydney), Frédéric Amant(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Rachel O’Connell(Royal Marsden NHS Foundation Trust), Yoland Antill(Peninsula Health), Alison Davis(Australian National University), Tania Moujaber(The University of Sydney), Catherine J. Kennedy(The University of Sydney), Philip Beale(The University of Sydney), Linda Mileshkin(Peter MacCallum Cancer Centre), Tony Bonaventura(St Vincent’s Private Hospital Sydney), Peter Grant(The University of Melbourne), Orla McNally(Royal Women's Hospital), King Tan(Apple (Israel)), James Scurry, Katrin Marie Sjoquist(Australian Research Council), Jeffrey C. Goh(The University of Queensland), Peter Sykes(Christchurch Hospital)
Cited by 88
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k